Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) to develop a new treatment for drug-resistant gonorrhea

(Drugs for Neglected Diseases Initiative) Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks to a new partnership between the not-for-profit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. The announcement comes as the World Health Organization (WHO) releases alarming new data today showing that of 77 countrie...